Home » Stocks » THMO

ThermoGenesis Holdings, Inc. (THMO)

Stock Price: $2.46 USD 0.09 (3.80%)
Updated Mar 5, 2021 3:59 PM EST - Market closed
After-hours: $2.45 -0.01 (-0.41%) Mar 5, 6:41 PM
Market Cap 15.47M
Revenue (ttm) 9.52M
Net Income (ttm) -17.55M
Shares Out 6.71M
EPS (ttm) -3.86
PE Ratio n/a
Forward PE 2.28
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.46
Previous Close $2.37
Change ($) 0.09
Change (%) 3.80%
Day's Open 2.40
Day's Range 2.16 - 2.48
Day's Volume 513,293
52-Week Range 1.63 - 14.18

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 weeks ago

RANCHO CORDOVA, Calif., Feb. 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. ("ThermoGenesis" or the "Company") (Nasdaq: THMO), a market leader in automated cell processing tools and ser...

Seeking Alpha - 3 months ago

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

RANCHO CORDOVA, Calif., Nov. 12, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy ...

Benzinga - 6 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, LMNL, SONN, TTOO
Seeking Alpha - 6 months ago

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

RANCHO CORDOVA, Calif., Aug. 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.

PRNewsWire - 6 months ago

RANCHO CORDOVA, Calif., Aug. 11, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc.

Seeking Alpha - 7 months ago

ThermoGenesis Holdings: Many Short-Term Catalysts In Low-Float Stock

PRNewsWire - 8 months ago

RANCHO CORDOVA, Calif., June 23, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy ...

PRNewsWire - 8 months ago

RANCHO CORDOVA, Calif., June 8, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...

PRNewsWire - 9 months ago

RANCHO CORDOVA, Calif., May 28, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...

Seeking Alpha - 9 months ago

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 9 months ago

RANCHO CORDOVA, Calif., May 14, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy f...

Zacks Investment Research - 9 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: BDTX, NERV, SPT, ZYXI
Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in ThermoGenesis Holdings, Inc. (THMO).

Zacks Investment Research - 10 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CUE, LVGO, SMED, VNET
Benzinga - 10 months ago

Thermogenesis Holdings Inc (NASDAQ: THMO) shares are trading higher on Thursday.

Seeking Alpha - 11 months ago

ThermoGenesis Holdings, Inc. (THMO) CEO Chris Xu on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

The Reincarnation Of ThermoGenesis With A Better Mousetrap For CAR-T Manufacturing

About THMO

ThermoGenesis Holdings develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company operates through two segments, Device and Clinical Development. It manufactures a... [Read more...]

Industry
Medical Devices
Founded
1986
CEO
Xiaochun Xu
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
THMO
Full Company Profile

Financial Performance

In 2019, THMO's revenue was $13.05 million, an increase of 34.89% compared to the previous year's $9.67 million. Losses were -$9.50 million, -76.09% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for THMO stock is "Buy" and the 12-month stock price forecast is 8.50.

Price Target
$8.50
Analyst Consensus: Buy